A Study of 5-FU Versus MTX+5-FU in Gastric Cancer With Peritoneal Metastasis
Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU)
Sponsor: Japan Clinical Oncology Group
Listed as NCT00149201, this PHASE3 trial focuses on Gastric Cancer and Neoplasm Metastasis and remains completed. Sponsored by Japan Clinical Oncology Group, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Japan Clinical Oncology Group
- Ministry of Health, Labour and Welfare, Japan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
1-1,Kanokoden,Chikusa-ku,Nagoya, Japan , 1-1,Seiryo-machi,Aoba-ku,Sendai, Japan , 1-1-2,Nakao,Asahi-ku,Yokohama, Japan , 1-4-1,Ueda,Morioka, Japan , 1-5-8,Hatanodai,Shinagawa-ku, Japan , 1007,Shimonagakubo,Nagaizumi-cho,Sunto-gun, Japan , 13,Horinouchi,Matsuyama, Japan , 13-70,Kitaouji-cho,Akashi, Japan , 18,Kuriyado,Kake-machi,Okazaki, Japan , 1800,Aoyagi,Yamagata, Japan and 24 more locations